Tesamorelin vs Sermorelin: Which One Fits Your Goal?

The Short Answer

If the thing you want to change is deep abdominal fat, the kind that sits behind the muscle wall and pushes the waistband out, tesamorelin is the one with evidence. Two Phase 3 trials measured that exact compartment with CT scans and watched it shrink. If you want a conservative lift to your own nighttime growth hormone pulse, with sleep, recovery, and skin as the hoped-for payoffs, sermorelin is the simpler fit and has the longer clinical history. If the goal is a lower number on the scale, neither is the right tool. The FDA label for tesamorelin says so in plain words.

Some pages ranking for this comparison come from clinics that carry only one of the two, and most treat tesamorelin as the pricier upgrade. We prescribe both, and both are $229 for a one-month vial. With nothing to upsell, the uncomfortable parts are easier to say. The famous tesamorelin numbers come from one specific patient population. The adult data on sermorelin is thin. And some people asking this question need a different tool entirely.

Tesamorelin vs Sermorelin at a Glance

If ipamorelin is also on your shortlist, the three-way decision lives in sermorelin vs ipamorelin vs tesamorelin Read nextSermorelin vs Ipamorelin vs Tesamorelin: Which Fits?All three raise your own growth hormone, but they pull different levers, last for different amounts of time, and suit different goals. This is a decision guide, not a spec sheet: match the peptide to what you actually want.Read article . The other pairings have their own pages: ipamorelin vs sermorelin Read nextIpamorelin vs Sermorelin 2026: Which GH Peptide Wins?Both peptides stimulate your pituitary gland to release growth hormone. But they work through different receptors, peak at different speeds, and suit different patients. Here is a direct comparison based on the pharmacology, not marketing.Read article , CJC-1295 vs sermorelin Read nextCJC-1295 vs Sermorelin 2026: Which GH Peptide Wins?Both stimulate your pituitary gland to produce more growth hormone. Both are GHRH receptor agonists. The CJC-1295 in the PeRx combo is the no-DAC version (Modified GRF 1-29), so both peptides are short-acting and pulsatile. The real differences are CJC-1295/Ipamorelin's dual-pathway design and greater enzyme resistance. Here is the honest comparison.Read article , and tesamorelin vs CJC-1295 Read nextTesamorelin vs CJC-1295/Ipamorelin 2026: FDA vs DualTesamorelin is the only FDA-approved growth hormone peptide. CJC-1295/Ipamorelin is the most popular compounded GH stack. Both stimulate your pituitary to produce growth hormone, but they do it differently and they have very different regulatory histories. Here is the honest comparison to help you choose.Read article .

Same Receptor, Different Engineering

Your hypothalamus tells your pituitary to release growth hormone with a 44-amino-acid messenger called GHRH. The message is fragile. An enzyme named DPP-IV clips it within minutes, which is fine for a signal that travels a few millimeters and a problem for anything injected under the skin. Tesamorelin and sermorelin are two answers to that fragility, from opposite directions.

Sermorelin trims. The first 29 amino acids of GHRH carry the full activity of the whole chain, and sermorelin is exactly that fragment. It behaves like the natural signal: it binds, the pituitary fires one pulse, and the peptide is gone in roughly 10 to 12 minutes.

Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. View study

Tesamorelin armors. It keeps all 44 amino acids and attaches a small hexenoyl group to the first one, which blocks the enzyme from its cutting site. The original Egrifta label puts the half-life at 26 minutes in healthy volunteers and 38 minutes in patients with HIV. Still short. It is a longer knock on the same door, and in the pivotal trial it raised IGF-1 by 81 percent over 26 weeks.

EGRIFTA (tesamorelin for injection) prescribing information. Theratechnologies Inc. Section 11 (description) and section 12.3 (pharmacokinetics): mean elimination half-life of 26 minutes in healthy subjects and 38 minutes in HIV-infected patients. View study

What they share matters more for safety. Both work upstream of the pituitary, so growth hormone still comes out in pulses and the natural brake, somatostatin, still caps each one. Neither is growth hormone. No published trial we could find compares them head to head, so any "tesamorelin is X times stronger" figure online is a guess assembled from separate studies.

The Evidence Gap Is the Real Difference

Tesamorelin is the rare compounded peptide whose results question has a published answer. In the pivotal trial, 412 patients with HIV and abdominal fat accumulation injected 2 mg or placebo daily for 26 weeks. Visceral fat on CT fell 15.2 percent on tesamorelin and rose 5.0 percent on placebo, and triglycerides dropped 50 mg/dL. A second Phase 3 trial in 404 patients found 10.9 percent against 0.6, reaching roughly 18 percent in those who continued for a year. Patients quietly switched to placebo at week 26 fared differently: in the authors’ words, the improvements were rapidly lost. Tesamorelin results Read nextTesamorelin Results: What the Trials Actually ShowedSearch for results on almost any peptide and you get mouse studies and marketing. Tesamorelin is the exception. The molecule went through two Phase 3 randomized trials with more than 800 patients, and the endpoint was not a survey or a scale. It was visceral fat measured by CT scan. This article walks through those numbers, the population they came from, what a realistic timeline looks like, and why the honest version of "tesamorelin before and after" involves a tape measure instead of a mirror.Read article walks through the full numbers.

Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. View study

Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. View study

Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-4779. View study

Sermorelin’s strong data sits elsewhere. It was approved as a diagnostic agent in 1990 and as Geref in 1997 for children with growth hormone deficiency, so its ability to make a pituitary release growth hormone is well documented. The adult file rests on three small studies from the 1990s, run with GHRH(1-29) or a close analog at doses and schedules that do not match a modern compounded protocol.

Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. View study

Vittone J, Blackman MR, Busby-Whitehead J, et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. View study

Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. View study

Forty people in total, no imaging, nothing longer than 16 weeks. No published study has put adults on sermorelin through a CT scanner to see what happened to their visceral fat. That is an absence of evidence, not proof it does nothing, but it makes any claim about sermorelin and belly fat an inference from physiology. Sermorelin benefits Read nextSermorelin Benefits: What the Research SupportsSearch for sermorelin benefits and you will find the same list on every clinic website: sleep, muscle, fat loss, skin, energy. What almost none of those pages tell you is how strong the evidence behind each claim actually is. This guide grades every major benefit against the published human research, names the honest size of each effect, and is just as specific about what sermorelin will not do.Read article grades each claimed benefit against this same small literature.

Belly Fat, Weight, Sleep: Match the Peptide to the Goal

Goal: a smaller waist at roughly the same weight

This is tesamorelin’s lane. The compartment it changed in trials is visceral fat, while the pinchable layer under the skin was essentially untouched. A good result looks like a smaller waist measurement, better triglycerides, and a scale that barely moves. It was measured over six months of daily injections, so it suits nobody who plans to judge it in week five.

Goal: losing weight

Neither one. The Egrifta label states that tesamorelin is "not indicated for weight loss management" because its effect on weight is neutral, and body weight did not change in the six-week or the 16-week GHRH(1-29) studies either. If the scale is the target, start with do peptides help you lose weight Read nextDo Peptides Help You Lose Weight? An Honest AnswerSome peptides genuinely help people lose weight. Most of the ones sold online do not. The line between the two is not marketing, it is drug class, and you can learn where it sits in about ten minutes. This page gives the verdict first and the reasoning after.Read article and the fat loss comparison Read nextBest Peptides for Fat Loss: Ranked by EvidenceMost rankings of fat-loss peptides are marketing dressed up as science. This one is built the way a prescribing clinic actually thinks: four tiers, ordered by the strength of the human evidence, with an honest section on the peptides that are not worth your money at all.Read article .

Goal: sleep, recovery, skin, a general reset

This is where sermorelin is usually prescribed, and the reasoning is more physiological than trial-based. The largest growth hormone pulse of the day arrives with the first stretch of deep sleep, and a short-acting bedtime dose is built to ride that pulse and then clear. The 16-week study recorded thicker skin in both sexes. It also recorded no change in questionnaire-rated sleep quality, which is worth knowing before you buy it as a sleep aid.

What Daily Life Looks Like on Each

The pharmacology overlaps. The routines do not, and for many people the routine ends up deciding it.

Sermorelin at PeRx is prescribed as 20 units (0.2 mL, 600 mcg) under the skin at bedtime, Monday through Friday. It goes in on an empty stomach, at least two hours after your last meal, with nothing to eat afterward, because a recent meal blunts the response the injection is meant to amplify. The cycle runs three months on and one month off. A 5 mL vial holds exactly 25 of those doses, five weeks of weekdays. The unit math is in the sermorelin dosage chart Read nextSermorelin Dosage Chart: Units, Timing, CostMost sermorelin dosage charts online are written for a powder you mix yourself. PeRx ships a ready-to-use vial at one fixed concentration, so the math is different and simpler. This page converts micrograms to insulin-syringe units at that concentration, explains why the dose is timed to bedtime on an empty stomach, compares nightly dosing to five on and two off, and lays out what a month costs, as of August 27, 2026.Read article .

Tesamorelin is once a day, every day, weekends included. The approved labeling names the abdomen as the injection site and is silent on the hour, and neither Phase 3 trial required a set time or an empty stomach. Morning suits some people and bedtime suits others. Hitting the same slot daily matters more than which slot it is. The trials used 2 mg, your own dose is whatever your prescription label says, and the tesamorelin dosage chart Read nextTesamorelin Dosage Chart: Units, Timing, CostTesamorelin dosing numbers found online disagree with each other for a reason: three different Egrifta labels say 2 mg, 1.4 mg, and 1.28 mg, and none of them describe a compounded vial. This page sorts out the three labels, converts milligrams to insulin-syringe units at the 3 mg/mL concentration PeRx ships, and covers timing, cycle length, missed doses, and what a month costs, as of August 31, 2026.Read article converts it into syringe units. Site rotation is covered in where to inject tesamorelin Read nextWhere to Inject Tesamorelin: Sites and RotationTesamorelin is the rare peptide with FDA-approved labeling that tells you exactly where it goes: a subcutaneous injection into the abdomen, rotated. As of July 2026, that approved route is the anchor for how patients use it. Here is the practical site map, the rotation habit that keeps absorption consistent, and the technique details patients ask about after their first vial arrives.Read article and where to inject sermorelin Read nextWhere to Inject Sermorelin: Sites, TimingSermorelin is a subcutaneous injection, usually taken once at bedtime. The four standard sites all work, but the timing detail is what makes sermorelin different from a daytime peptide. Here is the practical guide patients ask for after their first vial arrives, as of July 2026.Read article .

Side Effects and the Glucose Question

The early side effects look alike, because both peptides raise growth hormone and most of the list follows from that: redness or itching at the injection site, some fluid retention, achy joints, tingling in the hands. Tesamorelin has the better-quantified list because it has a modern FDA label. Across the pooled 26-week trials, injection site reactions occurred in 17 percent of tesamorelin patients against 6 percent on placebo. Joint pain was 13 percent against 11. Peripheral swelling, muscle pain, and tingling each ran 5 to 6 percent against 2.

Glucose is where the two separate. Read one at a time, the Phase 3 papers reported no significant difference in glycemic measures. The pooled data on the FDA label is sharper: 5 percent of tesamorelin patients crossed an HbA1c of 6.5 percent by week 26, compared with 1 percent on placebo, a hazard ratio of 3.3. The label tells prescribers to evaluate glucose status before starting and recheck it periodically, and reports that 47 percent of patients had IGF-1 more than two standard deviation scores above the mean at 26 weeks. The 12-month trial in adults without HIV saw no change in fasting glucose or HbA1c, in only 60 people.

EGRIFTA SV (tesamorelin for injection) prescribing information. Theratechnologies Inc. Revised July 2019. Sections 5.2 (elevated IGF-1), 5.4 (glucose intolerance or diabetes mellitus), and 6.1 (adverse reactions). Half-life figures are from the original EGRIFTA label, section 12.3. View study

Sermorelin’s list comes from the Geref years. The 1999 review of that literature names transient facial flushing and pain at the injection site as the most commonly reported events. In the adult studies, fasting glucose did not change over 14 days or over 16 weeks, insulin sensitivity improved in the men in the longer trial, and the only adverse effect it reported was a transient rise in blood lipids. Keep the sample sizes in mind. A clean result in 19 people is weaker reassurance than it sounds.

What the Intake Review Looks At

A licensed provider reviews your intake before either peptide is prescribed, and the questions map onto the risks above: cancer history, pregnancy, pituitary history, current medications, and the goal. For tesamorelin the glucose answers carry extra weight, since someone with diabetes or a borderline HbA1c is exactly who the label warning describes. For sermorelin, thyroid status matters more.

Three labs are worth having on file first, ordered through your own physician: IGF-1, fasting glucose, and HbA1c. An IGF-1 already near the top of the age-adjusted range is a reason to skip this whole category, and the aim on treatment is a value inside that range, not a high one. Lab work before starting peptides Read nextLab Work Before Starting PeptidesThe honest answer to "what bloodwork do I need before peptides?" is: it depends on the peptide, and for many of them the answer is none. Some sites will tell you to buy a full baseline panel before anything, because they sell the panel. Here is the real picture, which peptides typically need no labs, where a provider may want to check IGF-1 and a metabolic panel, and why the decision belongs to the provider reviewing your history rather than to a checklist.Read article has the detail.

Switching, Alternating, or Taking Both

Taking both at once. Prescribers do not usually pair them. They compete for the same receptor, and somatostatin caps how hard the pituitary responds no matter how many molecules are knocking. Two GHRH analogs together buy more side-effect exposure and very little extra growth hormone.

Alternating them. Weekdays on one and weekends on the other, or swapping month by month, has never been studied and has no mechanism behind it. It also works against the one thing the tesamorelin trials showed clearly: the visceral fat result depends on continuous use.

Switching from sermorelin to tesamorelin. This is the common direction, usually after a sermorelin cycle makes it clear the real goal was the midsection. Both clear the body within hours, so there is no washout to wait through. A switch is a new prescription and gets the same intake review as the first, glucose questions included.

Adding a second pathway instead. If the aim is a bigger growth hormone response, the add-on with a rationale is a different receptor. In 1990, a ghrelin-pathway peptide given with GHRH produced more growth hormone in healthy men than the two given separately would predict. That is the logic behind pairing a GHRH analog with ipamorelin, and it is why PeRx offers a tesamorelin/ipamorelin blend Read nextTesamorelin/Ipamorelin: Dosage and Cost (2026)Tesamorelin is the only FDA-approved GHRH analog, and the only GH peptide with Phase 3 trial data on visceral fat. This guide pairs it with Ipamorelin and focuses on what tesamorelin is actually proven to do: shrink deep abdominal fat, lower liver fat, and drive metabolic recomposition. If you want a general GH-support stack, the CJC-1295/Ipamorelin guide covers that. This page is about the FDA-approved, visceral-fat side of the GH peptide world.Read article at $299 alongside CJC-1295/ipamorelin Read nextCJC-1295 Ipamorelin: The Complete GuideCJC-1295 Ipamorelin pairs a GHRH signal that primes growth hormone release with a clean pulse trigger that fires it. After age 30, your body produces roughly 15% less growth hormone every decade. This stack doesn't replace what you've lost with synthetic hormones. It tells your body to start making more of its own again. Together, the two peptides form the most popular growth hormone optimization protocol in peptide therapy.Read article . The blends have no trials of their own, so more pathways also means more unknowns.

Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. View study

When the answer is neither. If you want weight loss, compete in a tested sport, have an active cancer history, or expect the effects of injected growth hormone, neither peptide is the right purchase. Sermorelin vs HGH Read nextSermorelin vs HGH: How They Really DifferBoth raise growth hormone, but they do it in opposite ways. Sermorelin is a GHRH analog that asks your own pituitary to release growth hormone in natural pulses, so your feedback control stays intact. Synthetic HGH is the finished hormone injected straight into circulation, which overrides that control. Here is the honest, mechanism-first comparison.Read article explains why a signal to the pituitary has a ceiling that direct hormone replacement does not.

Cost: Identical at PeRx

Most comparisons score price as a point for sermorelin, because tesamorelin is usually the more expensive of the two and branded Egrifta is a specialty drug priced for insurers. At PeRx they cost the same: $229 for a one-month vial of either tesamorelin Explore PeRxTesamorelinMetabolic Optimization PeptideView peptide or sermorelin Explore PeRxSermorelinThe Growth Hormone OptimizerView peptide , both 5 mL at 3 mg/mL. The price covers the provider review, compounding at a US 503A pharmacy, refrigerated overnight shipping, syringes, and swabs. Checkout saves your card, and the charge runs only if a provider approves the prescription.

Common Questions